A Phase 3, Open-label, Single-Arm Trial to Evaluate the Safety, Tolerability and Immunogenicity of 2 and 3 Doses of 13vPnC in HIV-Infected Subjects 6 Years of Age and Older Who Have Not Been Previously Immunized With Pneumococcal Vaccine

The study will evaluate the safety, tolerability and immunogenicity of a 13-valent
pneumococcal conjugate vaccine (13vPnC) in HIV-infected subjects 6 years of age or older who
have not been previously immunized with a pneumococcal vaccine. All subjects will receive 3
doses of 13vPnC and 1 dose of 23-valent pneumococcal polysaccharide vaccine (23vPS), with
each dose given approximately 1 month apart.